T0	Limitation 30805 30812	Whether
T1	Limitation 30691 30693	It
T2	Population 30720 30751	appropriate patient populations
T3	OutcomeMeasures 30756 30772	outcome measures
T4	Generalization 30805 30913	Whether quilizumab could have a clinically meaningful effect in another subgroup of allergic asthma patients
T5	StudyDuration 30917 30979	whether a treatment period beyond 36Â weeks would show efficacy
